BlackThorn Therapeutics Obtains $14,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=334764f5-50e0-4317-b6f4-8c836d9e35e2 - Date
1/6/2017 - Company Name
BlackThorn Therapeutics - Mailing Address
329 Oyster Point Blvd 3rd Floor South San Francisco, CA 94080 USA - Company Description
BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments. - Website
http://www.blackthornrx.com - Transaction Type
Venture Equity - Transaction Amount
$14,000,000 - Transaction Round
Series A - Proceeds Purposes
BlackThorn plans to use the additional funding to progress its lead clinical-stage asset, BTRX-246040, through Phase 2 clinical development, as well as to conduct additional exploratory pilot studies in targeted indications. - M&A Terms
- Venture Investor
GV - Venture Investor
Biomatics Capital partners
